165 related articles for article (PubMed ID: 15705716)
1. Vaccinia viruses with a serpin gene deletion and expressing IFN-gamma induce potent immune responses without detectable replication in vivo.
Legrand FA; Verardi PH; Chan KS; Peng Y; Jones LA; Yilma TD
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2940-5. PubMed ID: 15705716
[TBL] [Abstract][Full Text] [Related]
2. Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.
Legrand FA; Verardi PH; Jones LA; Chan KS; Peng Y; Yilma TD
J Virol; 2004 Mar; 78(6):2770-9. PubMed ID: 14990697
[TBL] [Abstract][Full Text] [Related]
3. Development of safe and efficacious viral vaccines for animals.
Yilma T; Verardi P; Jones L
Crit Rev Immunol; 2010; 30(3):223-37. PubMed ID: 20370631
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia virus serpins B13R (SPI-2) and B22R (SPI-1) encode M(r) 38.5 and 40K, intracellular polypeptides that do not affect virus virulence in a murine intranasal model.
Kettle S; Blake NW; Law KM; Smith GL
Virology; 1995 Jan; 206(1):136-47. PubMed ID: 7831769
[TBL] [Abstract][Full Text] [Related]
5. IL-18 expression results in a recombinant vaccinia virus that is highly attenuated and immunogenic.
Verardi PH; Legrand FA; Chan KS; Peng Y; Jones LA; Yilma TD
J Interferon Cytokine Res; 2014 Mar; 34(3):169-78. PubMed ID: 24168450
[TBL] [Abstract][Full Text] [Related]
6. Vaccinia virus serpins B13R and B22R do not inhibit antigen presentation to class I-restricted cytotoxic T lymphocytes.
Blake NW; Kettle S; Law KM; Gould K; Bastin J; Townsend AR; Smith GL
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2393-8. PubMed ID: 7561783
[TBL] [Abstract][Full Text] [Related]
7. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.
Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G
J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity.
Verardi PH; Jones LA; Aziz FH; Ahmad S; Yilma TD
J Virol; 2001 Jan; 75(1):11-8. PubMed ID: 11119568
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of the type I interferons alpha4, beta, and epsilon on antiviral activity and vaccine efficacy.
Day SL; Ramshaw IA; Ramsay AJ; Ranasinghe C
J Immunol; 2008 Jun; 180(11):7158-66. PubMed ID: 18490714
[TBL] [Abstract][Full Text] [Related]
11. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever.
Kettle S; Alcamí A; Khanna A; Ehret R; Jassoy C; Smith GL
J Gen Virol; 1997 Mar; 78 ( Pt 3)():677-85. PubMed ID: 9049422
[TBL] [Abstract][Full Text] [Related]
12. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
Harrington LE; Most Rv Rv; Whitton JL; Ahmed R
J Virol; 2002 Apr; 76(7):3329-37. PubMed ID: 11884558
[TBL] [Abstract][Full Text] [Related]
13. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
14. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity.
Reading PC; Smith GL
J Virol; 2003 Sep; 77(18):9960-8. PubMed ID: 12941906
[TBL] [Abstract][Full Text] [Related]
15. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
16. The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model.
Symons JA; Adams E; Tscharke DC; Reading PC; Waldmann H; Smith GL
J Gen Virol; 2002 Nov; 83(Pt 11):2833-2844. PubMed ID: 12388820
[TBL] [Abstract][Full Text] [Related]
17. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma.
Chen B; Timiryasova TM; Haghighat P; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
J Immunother; 2001; 24(1):46-57. PubMed ID: 11211148
[TBL] [Abstract][Full Text] [Related]
18. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence.
Symons JA; Tscharke DC; Price N; Smith GL
J Gen Virol; 2002 Aug; 83(Pt 8):1953-1964. PubMed ID: 12124459
[TBL] [Abstract][Full Text] [Related]
19. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
20. Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice.
Leist TP; Eppler M; Zinkernagel RM
J Virol; 1989 Jun; 63(6):2813-9. PubMed ID: 2542591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
